BSX vs MDT
BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | BSX | MDT | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $49.01 | $92.90 | |
| Market cap as of 2026-08-25 | $71.0B | $118.9B | |
| P/E as of 2026-08-25 | 20.40 | 24.25 | BSX lower |
| PEG as of 2026-08-25 | 0.44 | 3.09 | BSX lower |
| Net margin as of 2026-08-25 | +17.5% | +13.2% | BSX higher |
| Gross margin as of 2026-08-25 | +69.5% | +65.8% | BSX higher |
| Operating margin as of 2026-08-25 | +19.8% | +17.8% | BSX higher |
| ROE as of 2026-08-25 | +14.9% | +9.8% | BSX higher |
| ROA as of 2026-08-25 | +8.3% | +5.2% | BSX higher |
| Debt / equity as of 2026-08-25 | 0.51 | 0.57 | BSX lower |
| Revenue growth (YoY) as of 2026-08-25 | +13.5% | +8.4% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +16.5% | +5.2% | BSX higher |
| Dividend yield as of 2026-08-25 | n/a | +3.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-25 | 0.57 | 0.57 | |
| 1-year return as of 2026-08-24 close | -53.8% | +0.2% | MDT higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.